Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Evidence based approach to the treatment of community-associated methicillin-resistant Staphylococcus aureus. Infect Drug Resist 2009;2:27-40

Date

01/01/2009

Pubmed ID

21694885

Pubmed Central ID

PMC3108727

DOI

10.2147/idr.s3794

Abstract

Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections have increased dramatically over the last two decades. The types of infections can range from complicated skin and skin structure infections (cSSSI) to pneumonia and endocarditis. Oral antimicrobial therapy, such as trimethoprim-sulfamethoxazole, clindamycin, long-acting tetracyclines, or linezolid may provide enhanced benefit to those with uncomplicated cutaneous lesions when used in conjunction with incision and drainage in an outpatient setting. However, resistance, susceptibilities, patient-specific circumstances, and adverse effects can impact a healthcare professional's choice of antibiotics. In patients with complicated infections requiring hospitalization or parenteral treatment, vancomycin remains the drug of choice, even though increased resistance and decreased efficacy have crept into clinical practice. Linezolid, quinupristin/dalfopristin, daptomycin, and tigecycline are alternative intravenous agents for the treatment of CA-MRSA. Investigational agents such as dalbavancin, telavancin, oritivancin, iclaprim, ceftobiprole, ceftaroline, and others may expand our therapeutic armamentarium for the treatment of infections caused by CA-MRSA in the future.

Author List

Peppard WJ, Daniels A, Fehrenbacher L, Winner J

Author

William J. Peppard PharmD Trauma/Surgical Critical Care Pharmacist in the Pharmacy department at Froedtert Hospital




jenkins-FCD Prod-468 69a93cef3257f26b866d455c1d2b2d0f28382f14